Monitoring patients on methotrexate: Hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen

British Journal of Dermatology

Volumn 152, Issue 3, 2005, Pages 451-458

  Maurice, P D L ^a,f   Maddox, A J ^b   Green, C A ^c   Tatnall, F ^d   Schofield, J K ^a   Stott, D J ^e  

^a St Albans City Hospital   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c LISTER HOSPITAL   (United Kingdom)

^d WATFORD GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^f CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Aminoterminal peptide of type III procollagen; Liver biopsy; Liver fibrosis; Methotrexate

Indexed keywords

COLLAGEN TYPE 3; METHOTREXATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; AGED; ARTICLE; ASSAY; BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; COHORT ANALYSIS; COLLAGEN SYNTHESIS; COMPARATIVE STUDY; DETERIORATION; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG CONTRAINDICATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; PATIENT MONITORING; PEMPHIGUS FOLIACEUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; RELIABILITY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOPSY; DERMATOLOGIC AGENTS; DRUG MONITORING; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; LONG-TERM CARE; MALE; METHOTREXATE; MIDDLE AGED; PATIENT SELECTION; PEPTIDE FRAGMENTS; PRACTICE GUIDELINES; PROCOLLAGEN; PSORIASIS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 17444383441     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06459.x     Document Type: Article

References (27)

1. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19:145-56.
2. Roenigk HH Jr, Auerbach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38:478-85.
3. Gilmore IT, Burroughs A, Murray-Lyon IM et al. Indications, methods and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36:437-41.
4. Carmichael AJ, Motley RJ, Finlay AY et al. Methotrexate associated hepatic complications and monitoring protocols in UK dermatology. Br J Dermatol 1992; 127 (Suppl. 40): 18 (Abstr.).
5. Mitchell D, Johnson RJ, Testa HJ et al. Ultrasound and radionuclide scans-poor indicators of liver damage in patients treated with methotrexate. Clin Exp Dermatol 1987; 12:243-5.
6. van Dooren-Greebe RJ, Kuijpers AL, Buijs WC et al. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. Br J Dermatol 1996; 134:481-7.
7. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-75.
8. Myers RP, Tainturier M-H, Ratziu V et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39:222-30.
9. Rossi E, Adams L, Prins A et al. Validation of the Fibrotest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003; 49:450-4.
10. Mitchell D, Smith A, Rowan B et al. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Br J Dermatol 1990; 122:1-7.
11. 1 Zachariae H, Aslam HM, Bjerring P et al. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991; 25:50-3.
12. Boffa MJ, Smith A, Chalmers RJG et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996; 135:538-44.
13. Zachariae H, Heickendorff L, Søgaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001; 143:100-3.
14. Niemelä O, Risteli L, Sotaniemi EA et al. Aminoterminal propeptide of type III procollagen in serum in alcoholic liver disease. Gastroenterology 1983; 85:254-9.
15. Zachariae H, Søgaard H, Heickendorff L. Methotrexate-induced liver cirrhosis. Dermatology 1996; 192:343-6.
16. Frei A, Zimmermann A, Weigand K. The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology 1984; 4:830-4.
17. Aithal GP, Haugk B, Das S et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther 2004; 19:391-9.
18. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21:3-16.
19. Langman G, de la Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001; 16:1395-401.
20. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37:1502-19.
21. Babbs C, Hunt L, Haboubi NY et al. Type III procollagen peptide: a marker of disease activity and prognosis in primary biliary cirrhosis. Lancet 1988; i: 1021-4.
22. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-4.
23. Ishak KG, Baptista A, Blanch L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-9.
24. Oogarah PK, Rowland PL, Mitchell DM et al. Abnormalities of serum type III procollagen aminoterminal peptide in methotrexate-treated psoriatic patients with normal liver histology do not correlate with hepatic ultrastructural changes. Br J Dermatol 1995; 133:512-18.
25. Hertel NT, Stoltenberg M, Juul A et al. Serum concentrations of type I and III procollagen propeptides in healthy children and girls with central precocious puberty during treatment with gonadotrophin-releasing hormone analog and cyproterone acetate. J Clin Endocrinol Metab 1993; 76:924-7.
26. Ulrich D, Noah EM, Burchardt ER et al. Serum concentration of amino-terminal propeptide of type III procollagen as a prognostic marker for skin fibrosis after scar correction in burned patients. Burns 2002; 28:766-71.
27. Uusimaa P, Risteli J, Niemelä M et al. Collagen scar formation after acute myocardial infarction. Circulation 1997; 96:2565-72.